SEC filings and other documents

Record 40% Q2 gross margin and a 92% net-loss reduction mark the turnaround.

Record 40% gross margin and a $144,000 Q2 loss mark a turnaround inflection.

Record gross margin and strong revenue growth highlight a successful turnaround and expansion.

Record gross margins and strong contract growth position the business for sustained profitability.

Record 40% gross margin and $54.3M revenue highlight a successful turnaround and global expansion.

Turnaround drives margin gains and nationwide healthcare expansion, supporting profitable growth.

All board nominees and proposals were approved by majority vote; results to be filed in Form 8-K.

Turnaround delivers margin expansion, cost cuts, and nationwide healthcare growth.

Record gross margins and improved profitability mark a successful operational turnaround.

Turnaround drives margin growth, nationwide expansion, and global e-commerce momentum.

Turnaround delivers cost cuts, margin gains, and nationwide healthcare expansion for 2026 growth.

Shareholders approved flexible reverse stock split authority for the board through March 2028.

Expanding global healthcare and e-commerce with strong growth, innovation, and cost efficiency.

Cost reductions and margin-focused growth strategies position the business for profitability in 2026.

Revenue fell 11% in Q3, but cost cuts and segment gains set up a stronger Q4 and 2026.

Revenue down on healthcare softness; e-commerce and cost cuts drive future focus.

73% revenue growth in 2024 driven by healthcare and global e-commerce expansion.

Revenue fell to $14.5M as tariffs and healthcare headwinds pressured growth; e-commerce recurring revenue rose 51%.